{'52WeekChange': 0.06453228,
 'SandP52WeekChange': None,
 'address1': '222 Berkeley Street',
 'address2': '12th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 20.93,
 'askSize': 800,
 'averageDailyVolume10Day': 174212,
 'averageVolume': 197606,
 'averageVolume10days': 174212,
 'beta': 0.947772,
 'beta3Year': None,
 'bid': 20.91,
 'bidSize': 800,
 'bookValue': 5.741,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 21.27,
 'dayLow': 20.71,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.568,
 'enterpriseToRevenue': None,
 'enterpriseValue': 669304256,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '857 264 4299',
 'fiftyDayAverage': 21.861286,
 'fiftyTwoWeekHigh': 25.86,
 'fiftyTwoWeekLow': 12.99,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 25331179,
 'forwardEps': -2.46,
 'forwardPE': -8.512196,
 'fromCurrency': None,
 'fullTimeEmployees': 70,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.06734,
 'heldPercentInstitutions': 1.01052,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/rhythmtx.com',
 'longBusinessSummary': 'Rhythm Pharmaceuticals, Inc., a biopharmaceutical '
                        'company, focuses on the development and '
                        'commercialization of therapeutics for the treatment '
                        "of rare genetic disorders. The company's lead product "
                        'candidate is setmelanotide, a melanocortin-4 '
                        'receptor, which is in Phase III clinical trials to '
                        'treat pro-opiomelanocortin (POMC) and leptin receptor '
                        'deficiency obesity, and Bardet-Biedl and Alstr√∂m '
                        'syndrome; and is in Phase II clinical trials for '
                        'treating POMC or LEPR heterozygous deficiency '
                        'obesities, steroid receptor coactivator 1 deficiency '
                        'obesity, SH2B1 deficiency obesity, MC4 receptor '
                        'deficiency obesity, Smith-Magenis syndrome obesity, '
                        'POMC epigenetic disorders, and other MC4R disorders. '
                        'It is also developing RM-853, an orally available '
                        'ghrelin o-acyltransferase inhibitor that is in '
                        'preclinical development for Prader-Willi syndrome. '
                        'The company was formerly known as Rhythm Metabolic, '
                        'Inc. and changed its name to Rhythm Pharmaceuticals, '
                        'Inc. in October 2015. Rhythm Pharmaceuticals, Inc. '
                        'was founded in 2008 and is headquartered in Boston, '
                        'Massachusetts.',
 'longName': 'Rhythm Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 923282304,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_309184792',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -145919008,
 'nextFiscalYearEnd': 1640908800,
 'open': 21.11,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.4,
 'phone': '857 264 4280',
 'previousClose': 21.28,
 'priceHint': 2,
 'priceToBook': 3.647448,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 21.27,
 'regularMarketDayLow': 20.71,
 'regularMarketOpen': 21.11,
 'regularMarketPreviousClose': 21.28,
 'regularMarketPrice': 21.11,
 'regularMarketVolume': 123687,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 44091800,
 'sharesPercentSharesOut': 0.0398,
 'sharesShort': 1755675,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1565770,
 'shortName': 'Rhythm Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0572,
 'shortRatio': 7.09,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'RYTM',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.758,
 'twoHundredDayAverage': 18.998777,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '4f7e972d-a371-3965-97f4-9476f892bf61',
 'volume': 123687,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.rhythmtx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02116'}